Preparation method and application of functionalized calcium peroxide drug-loaded composite material capable of overcoming multidrug resistance of tumors
By preparing functionalized calcium peroxide drug-loading composite materials, the reaction of calcium peroxide with water inhibits the expression of P-glycoprotein, the problem of tumor multidrug resistance is solved and the concentration and efficacy of chemotherapy drugs in tumor cells are improved.
Patent Information
- Application Number
- CN202411149959.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
Multidrug resistance of tumor cells to chemotherapy drugs leads to poor chemotherapy efficacy, mainly caused by the overexpression of P-glycoprotein, and the prior art has failed to effectively solve this problem.
By preparing functionalized calcium peroxide drug-loading composite materials, calcium peroxide reacts with water to produce hydrogen peroxide and calcium ions, inhibit P-glycoprotein expression, reduce external pumps of chemotherapy drugs, improve hypoxia characteristics of tumor microenvironment, and improve chemotherapy Drug sensitivity.
Effectively reduce P-glycoprotein expression, enhance the concentration of chemotherapy drugs in tumor cells, improve the effect of chemotherapy, overcome multidrug resistance, and enhance the efficacy of chemotherapy.
Smart Images

Figure CN119015443A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of preparation of functionalized drug-carrying composite materials, and specifically relates to a preparation method and application of a functionalized calcium peroxide drug-carrying composite material for overcoming tumor multidrug resistance. Background Art
[0002] Malignant tumors (cancer) seriously threaten human life and health and are one of the major public health problems in my country. Chemotherapy is an effective cancer treatment strategy, but due to the widespread use of chemotherapeutic drugs, multidrug resistance (MDR) of tumor cells to chemotherapeutic drugs has emerged, resulting in unsatisfactory chemotherapy efficacy. A common mechanism of MDR is the overexpression of P-glycoprotein, which is a type of adenosine triphosphate-dependent membrane transport efflux pump called adenosine triphosphate-binding cassette (ABC) transporter. Overexpression of P-glycoprotein in tumor cells can pump chemotherapeutic drugs out of the cell, reduce the concentration of drugs in the cell, and thus weaken the effect of chemotherapy. Therefore, there is a need for a tumor treatment system that can reduce the expression of P-glycoprotein, thereby reducing drug efflux and enhancing the effect of chemotherapy. The present invention utilizes the property of calcium peroxide that can react with water. The reaction produces hydrogen peroxide and a large amount of calcium ions. The hydrogen peroxide decomposes to produce oxygen. The calcium ions induce mitochondrial dysfunction and inhibit the cell from producing energy. In addition, the calcium ions can also inhibit the activity of the complex in the respiratory chain, so that oxygen is enriched. The above process can cause the downregulation of P-glycoprotein expression, thereby overcoming tumor multidrug resistance and effectively ensuring the therapeutic effect of chemotherapy drugs. There are currently no related reports in this regard. Summary of the invention
[0003] The technical problem solved by the present invention is to provide a preparation method and application of a functionalized calcium peroxide drug-loaded composite material that has a simple synthesis process and is relatively low in price and can overcome tumor multidrug resistance. The functionalized calcium peroxide drug-loaded composite material prepared by the method reduces the content of chemotherapy drugs excreted by P-glycoprotein, while improving the hypoxic characteristics of the internal microenvironment of the tumor, inhibiting the expression of hypoxia-inducible factor, and ultimately achieving the purpose of inhibiting the expression of P-glycoprotein, thereby improving the therapeutic effect of the sensitivity of the tumor site to chemotherapy drugs, and can be used to prepare anticancer drugs that overcome multidrug resistance.
[0004] The present invention adopts the following technical solution to solve the above technical problems: a method for preparing a functionalized calcium peroxide drug-loaded composite material for overcoming multidrug resistance of tumors, characterized in that the specific process is as follows: Step S1: preparing a calcium chloride dihydrate solution and a sodium hyaluronate solution, dissolving the calcium chloride dihydrate solution and the sodium hyaluronate solution in a methanol solution and stirring to mix evenly, then adding a hydrogen peroxide solution and an ammonia solution, and continuing to stir until the solution turns blue, centrifuging and washing with methanol to obtain hyaluronic acid-coated calcium peroxide nanomaterials CaO2@HA NPs; Step S2: Take the hyaluronic acid-coated calcium peroxide nanomaterial CaO2@HA NPs obtained in step S1, add N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, and dissolve in secondary water, stir and mix in the dark to obtain a CaO2@HA NPs mixed solution, then add catalase solution and doxorubicin hydrochloride solution, stir and mix in the dark, and centrifuge and wash to obtain a composite material CaO2@HA-CAT-DOX; Step S3: Weigh folic acid and dissolve it in secondary water, then add N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir and mix evenly, then add the composite material CaO2@HA-CAT-DOX obtained in step S2, stir and mix evenly in the dark to obtain the functionalized calcium peroxide drug-loaded composite material CaO2@HA-CAT-DOX-FA.
[0005] A method for preparing a functionalized calcium peroxide drug-loaded composite material for overcoming tumor multidrug resistance, characterized in that the specific steps are: Step S1: prepare a 2 mol / L calcium chloride dihydrate solution and a 4 mg / mL sodium hyaluronate solution, dissolve 1 mL of the calcium chloride dihydrate solution and 1 mL of the sodium hyaluronate solution in 60 mL of a methanol solution, stir for 5-20 min, then add 0.5-1 mL of a 30 wt% hydrogen peroxide solution and 500 μL of an ammonia solution, continue stirring until the solution turns blue, centrifuge and wash with methanol to obtain hyaluronic acid-coated calcium peroxide nanomaterials CaO2@HA NPs; Step S2: Take 2 mg of the hyaluronic acid-coated calcium peroxide nanomaterial CaO2@HA NPs obtained in step S1, add 5 mg of N-hydroxysuccinimide and 10 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and dissolve in 2 mL of secondary water, stir in the dark for 30-60 min to obtain a CaO2@HA NPs mixed solution, take 1 mg of catalase, add 3 mL of secondary water and mix ultrasonically to obtain a catalase solution, take 1 mg of doxorubicin hydrochloride, dissolve in 2 mL of secondary water and mix ultrasonically to obtain a doxorubicin hydrochloride solution, add the catalase solution and the doxorubicin hydrochloride solution to the CaO2@HA NPs mixed solution, stir in the dark for 9-12 h, and then centrifuge and wash to obtain the composite material CaO2@HA-CAT-DOX; Step S3: Weigh 0.6 mg of folic acid and dissolve it in 2 mL of secondary water, then add 2 mg of N-hydroxysuccinimide and 4 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir for 50-60 min, then add the composite material CaO2@HA-CAT-DOX obtained in step S2, and stir in dark for 6-10 h to obtain the functionalized calcium peroxide drug-loaded composite material CaO2@HA-CAT-DOX-FA.
[0006] The functionalized calcium peroxide drug-carrying composite material of the present invention is used in the preparation of anticancer drugs that target and overcome tumor multidrug resistance.
[0007] Compared with the prior art, the present invention has the following advantages and beneficial effects: as the chemotherapy time increases, the tumor will gradually develop drug resistance, mainly due to the overexpression of P-glycoprotein in tumor cells, which discharges part of the chemotherapy drugs outside the tumor cells, reduces the concentration of chemotherapy drugs in the tumor cells, and thus the chemotherapy effect is poor. The present invention does not increase the intake of chemotherapy drugs, but achieves the expected therapeutic effect by inhibiting the expression of P-glycoprotein, reducing the amount of pumped drugs, and increasing the content of chemotherapy drugs inside tumor cells. The present invention utilizes the performance of calcium peroxide reacting with water. The reaction process produces hydrogen peroxide and a large amount of calcium ions. Hydrogen peroxide decomposes to produce oxygen. Calcium ions induce mitochondrial dysfunction to inhibit cell energy production. In addition, calcium ions can also inhibit the activity of complexes in the respiratory chain, so that oxygen is enriched. The above process can cause the expression of P-glycoprotein to be downregulated, thereby overcoming tumor multidrug resistance, and then effectively ensuring the therapeutic effect of chemotherapy drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 The scanning electron microscope and particle size distribution diagram of the hyaluronic acid-coated calcium peroxide nanomaterial prepared in Example 1; Figure 2 This is the XRD pattern of the hyaluronic acid-coated calcium peroxide nanomaterial prepared in Example 1; Figure 3 The UV-visible absorption spectra of the composite material CaO2@HA-CAT-DOX-FA prepared in Example 1 and the intermediate products in its synthesis process; Figure 4 Zeta potential of the composite material CaO2@HA-CAT-DOX-FA prepared in Example 1 and the intermediate product in its synthesis process; Figure 5 This is the oxygen generation curve of the composite material CaO2@HA-CAT-DOX prepared in Example 1; Figure 6 The release curve of chemotherapy drugs under different conditions for the composite material CaO2@HA-CAT-DOX prepared in Example 1; Figure 7 Western Blot of the composite material CaO2@HA-CAT-DOX-FA prepared in Example 1; Figure 8 This is a diagram showing the cell activity experiment of the composite material CaO2@HA-CAT-DOX-FA prepared in Example 1. DETAILED DESCRIPTION
[0009] The above contents of the present invention are further described in detail below through examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples, and all technologies implemented based on the above contents of the present invention belong to the scope of the present invention. Example 1
[0010] Preparation of hyaluronic acid-coated calcium peroxide nanomaterials: prepare 2 mol / L calcium chloride dihydrate solution and 4 mg / mL sodium hyaluronate solution, dissolve 1 mL of calcium chloride dihydrate solution and 1 mL of sodium hyaluronate solution in 60 mL of methanol solution, stir for 5-20 min, then add 0.5-1 mL of 30 wt% hydrogen peroxide solution and 500 μL of ammonia solution, continue stirring until the solution turns blue, centrifuge and wash with methanol to obtain hyaluronic acid-coated calcium peroxide nanomaterials CaO2@HANPs.
[0011] Modification of catalase and doxorubicin hydrochloride: Take 2 mg of the hyaluronic acid-coated calcium peroxide nanomaterial CaO2@HA NPs obtained in step S1, add 5 mg of N-hydroxysuccinimide (NHS) and 10 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), and dissolve in 2 mL of secondary water, stir in the dark for 30-60 min to obtain a CaO2@HA NPs mixed solution, take 1 mg of catalase (CAT), add 3 mL of secondary water and mix ultrasonically to obtain a catalase solution, take 1 mg of doxorubicin hydrochloride (DOX), dissolve in 2 mL of secondary water and mix ultrasonically to obtain a doxorubicin hydrochloride solution, add the catalase solution and the doxorubicin hydrochloride solution to the CaO2@HA NPs mixed solution, stir in the dark for 9-12 h, and then centrifuge and wash to obtain the composite material CaO2@HA-CAT-DOX.
[0012] Connect folic acid: weigh 0.6 mg of folic acid (FA) and dissolve it in 2 mL of secondary water, then add 2 mg of N-hydroxysuccinimide and 4 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir for 50-60 min, then add the composite material CaO2@HA-CAT-DOX obtained in step S2, and stir in the dark for 6-10 h to obtain the functionalized calcium peroxide drug-loaded composite material CaO2@HA-CAT-DOX-FA (abbreviated as CHCDF).
[0013] Figure 1 The scanning electron microscope image and particle size distribution diagram of the prepared hyaluronic acid-coated calcium peroxide nanomaterial show that spherical particles of about 94.5 nm are generated.
[0014] Figure 2 This is the XRD diagram of the prepared hyaluronic acid-coated calcium peroxide nanomaterial. From the standard card in the figure, it can be seen that the synthesized compound is calcium peroxide.
[0015] Figure 3 This is the UV-visible absorption spectrum of the prepared composite material CaO2@HA-CAT-DOX-FA and the intermediate product of its synthesis process. It can be seen from the figure that the composite material CaO2@HA-CAT-DOX-FA has characteristic absorption peaks of DOX and FA, indicating the successful loading of DOX and FA.
[0016] Figure 4 This is the Zeta potential diagram of the prepared composite material CaO2@HA-CAT-DOX-FA and the intermediate products in its synthesis process. The potential changes in the figure illustrate the successful synthesis of the composite material CaO2@HA-CAT-DOX-FA.
[0017] Figure 5 This is the oxygen generation curve of the prepared composite material CaO2@HA-CAT-DOX and the intermediate products of its synthesis process. It can be seen from the figure that when the composite material CaO2@HA-CAT-DOX is in the presence of hyaluronidase, the amount of hydrogen peroxide produced by calcium peroxide that is decomposed into oxygen is the largest, because hyaluronidase decomposes the coated hyaluronic acid and releases more calcium peroxide, which produces a large amount of hydrogen peroxide under acidic conditions and is then decomposed into oxygen under the action of catalase. The other groups produce less oxygen, proving that the composite material CaO2@HA-CAT-DOX has good oxygen production capacity.
[0018] Figure 6 The release curve of chemotherapy drugs under different conditions of the prepared composite material CaO2@HA-CAT-DOX. It can be seen from the figure that when the pH of the composite material CaO2@HA-CAT-DOX is 5.5, the release amount is 79.1%, which is much larger than the release amount of 17.2% at pH 7.4, indicating that the composite material CaO2@HA-CAT-DOX can achieve controllable release in the acidic microenvironment of the tumor.
[0019] Figure 7This is the Western Blot of the prepared composite material CaO2@HA-CAT-DOX-FA. It can be seen from the figure that the composite material CaO2@HA-CAT-DOX-FA can inhibit the expression of P-glycoprotein, increase the sensitivity of tumors to chemotherapy drugs, improve the chemotherapy effect and overcome tumor multidrug resistance.
[0020] Figure 8 This is the cell activity experimental diagram of the prepared composite material CaO2@HA-CAT-DOX-FA. It can be seen from the figure that CHCDF has a good inhibition rate on tumor cells.
[0021] The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for illustrating the principles of the present invention. Without departing from the scope of the principles of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of protection of the present invention.
Claims
1. A method for preparing a functionalized calcium peroxide drug-loaded composite material for overcoming tumor multidrug resistance, characterized in that The specific process is: Step S1: preparing a calcium chloride dihydrate solution and a sodium hyaluronate solution, dissolving the calcium chloride dihydrate solution and the sodium hyaluronate solution in a methanol solution and stirring to mix evenly, then adding a hydrogen peroxide solution and an ammonia solution, and continuing to stir until the solution turns blue, centrifuging and washing with methanol to obtain hyaluronic acid-coated calcium peroxide nanomaterials CaO2@HA NPs; Step S2: Take the hyaluronic acid-coated calcium peroxide nanomaterial CaO2@HA NPs obtained in step S1, add N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, and dissolve in secondary water, stir and mix in the dark to obtain a CaO2@HA NPs mixed solution, then add catalase solution and doxorubicin hydrochloride solution, stir and mix in the dark, and centrifuge and wash to obtain a composite material CaO2@HA-CAT-DOX; Step S3: Weigh folic acid and dissolve it in secondary water, then add N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir and mix evenly, then add the composite material CaO2@HA-CAT-DOX obtained in step S2, stir and mix evenly in the dark to obtain the functionalized calcium peroxide drug-loaded composite material CaO2@HA-CAT-DOX-FA.
2. The method for preparing a functionalized calcium peroxide drug-loaded composite material for overcoming tumor multidrug resistance according to claim 1, characterized in that The specific steps are: Step S1: prepare a 2 mol / L calcium chloride dihydrate solution and a 4 mg / mL sodium hyaluronate solution, dissolve 1 mL of the calcium chloride dihydrate solution and 1 mL of the sodium hyaluronate solution in 60 mL of a methanol solution, stir for 5-20 min, then add 0.5-1 mL of a 30 wt% hydrogen peroxide solution and 500 μL of an ammonia solution, continue stirring until the solution turns blue, centrifuge and wash with methanol to obtain hyaluronic acid-coated calcium peroxide nanomaterials CaO2@HA NPs; Step S2: Take 2 mg of the hyaluronic acid-coated calcium peroxide nanomaterial CaO2@HA NPs obtained in step S1, add 5 mg of N-hydroxysuccinimide and 10 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and dissolve in 2 mL of secondary water, stir in the dark for 30-60 min to obtain a CaO2@HA NPs mixed solution, take 1 mg of catalase, add 3 mL of secondary water and mix ultrasonically to obtain a catalase solution, take 1 mg of doxorubicin hydrochloride, dissolve in 2 mL of secondary water and mix ultrasonically to obtain a doxorubicin hydrochloride solution, add the catalase solution and the doxorubicin hydrochloride solution to the CaO2@HA NPs mixed solution, stir in the dark for 9-12 h, and then centrifuge and wash to obtain the composite material CaO2@HA-CAT-DOX; Step S3: Weigh 0.6 mg of folic acid and dissolve it in 2 mL of secondary water, then add 2 mg of N-hydroxysuccinimide and 4 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir for 50-60 min, then add the composite material CaO2@HA-CAT-DOX obtained in step S2, and stir in dark for 6-10 h to obtain the functionalized calcium peroxide drug-loaded composite material CaO2@HA-CAT-DOX-FA.
3. Use of the functionalized calcium peroxide drug-loaded composite material prepared according to the method of any one of claims 1 to 2 in the preparation of anticancer drugs that target and overcome tumor multidrug resistance.
Citation Information
Cited By
Magnetic response composite hydrogel for bone defect integrated repair and preparation method thereof
CN121648358A
